Settlement Order in respect Mr. Praveen Lingamneni and 7 others in the matter of Divis Laboratories Ltd


Quick Summary
This settlement order concerns eight individuals, including Praveen Lingamneni, who applied to resolve proceedings initiated by the Securities and Exchange Board of India (SEBI). The proceedings related to alleged violations of insider trading regulations concerning Divis Laboratories Ltd. The individuals are accused of trading the company's shares while in possession of Unpublished Price Sensitive Information (UPSI) regarding a USFDA import alert. They have settled these allegations without admitting or denying the findings.

Court :
SEBI

Brief :
Eight applicants (referred to above and hereinafter referred to as the “applicants”) filed settlement applications in terms of the SEBI (Settlement Proceedings) Regulations, 2018 (hereinafter referred to as the “Settlement Regulations”) proposing to settle, without admitting or denying the findings of fact and conclusions of law, through a settlement order, the pending proceedings initiated against the applicants under Sections 11(1), 11(4), 11B(1), 11B(2) and 11(4A) of the SEBI Act, 1992 vide impounding order cum Show Cause Notice dated July 01, 2020, for the violation of Regulations 3(1), 4(1) of the (Prohibition of Insider Trading) Regulations, 2015, Regulation 7(2) (a) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Clause 6 of the Minimum Standards for Code of Conduct as specified in Schedule B read with Regulation 9(1) of the SEBI (PIT) Regulations, 2015.

Citation :
SO / EFD-2 / SD /356/ OCTOBER / 2020

SO / EFD-2 / SD /356/ OCTOBER / 2020

BEFORE THE SECURITIES AND EXCHANGE BOARD OF INDIA

SETTLEMENT ORDER
in Settlement Applications bearing Nos.

 

1. 4150/2020– Praveen Lingamneni [PAN : AAWPL9203A]
2. 4151/2020– L Kishore Babu [PAN : AAFPL6754R]
3. 4152/2020– Nagesh Lingamneni [PAN : ABJPL5533F]
4. 4153/2020– Sri Lakshmi Lingamneni [PAN : ACZPL7827K]
5. 4154/2020– Radhika Dronavali [PAN : AKGPR0018R]
6. 4155/2020– D. Srinivas Rao [PAN : AEXPD7683R]
7. 4156/2020– Gopichand Lingamneni [PAN : ABPPL4081Q]
8. 4157/2020- Pushpa Latha Devi [PAN : AEVPL9622G]

in the matter of Divis Laboratories Ltd.

1. Eight applicants (referred to above and hereinafter referred to as the “applicants”) filed settlement applications in terms of the SEBI (Settlement Proceedings) Regulations, 2018 (hereinafter referred to as the “Settlement Regulations”) proposing to settle, without admitting or denying the findings of fact and conclusions of law, through a settlement order, the pending proceedings initiated against the applicants under Sections 11(1), 11(4), 11B(1), 11B(2) and 11(4A) of the SEBI Act, 1992 vide impounding order cum Show Cause Notice dated July 01, 2020, for the violation of Regulations 3(1), 4(1) of the (Prohibition of Insider Trading) Regulations, 2015, Regulation 7(2) (a) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Clause 6 of the Minimum Standards for Code of Conduct as specified in Schedule B read with Regulation 9(1) of the SEBI (PIT) Regulations, 2015.

2. It was observed during investigation that Divis Laboratories Ltd. had made an announcement during market hours on July 10, 2017 on the exchange platform titled ‘USFDA to Lift Import Alert 99-32’ on its Unit-II at Visakhapatnam’. The information was material in nature and fell within the definition of Unpublished Price Sensitive Information (UPSI). The applicants were identified as insiders who had directly or indirectly traded in the scrip of Divis Laboratories Ltd. during the UPSI period i.e. during July 07, 2017 to July 10, 2017.

3. Accordingly, the proceedings referred to in paragraph 1 were initiated against the applicants. The applicants have filed the settlement applications in respect of the aforesaid enforcement proceedings.

To konow more in details find the attachment file

FAQ :

The applicants are Praveen Lingamneni, L Kishore Babu, Nagesh Lingamneni, Sri Lakshmi Lingamneni, Radhika Dronavali, D. Srinivas Rao, Gopichand Lingamneni, and Pushpa Latha Devi.

The settlement order is in the matter of Divis Laboratories Ltd.

The alleged violations include Regulation 3(1) and 4(1) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, and other related provisions concerning the handling of Unpublished Price Sensitive Information (UPSI).

The UPSI related to Divis Laboratories Ltd.'s announcement on July 10, 2017, titled 'USFDA to Lift Import Alert 99-32' on its Unit-II at Visakhapatnam.

The applicants are identified as having traded in the scrip of Divis Laboratories Ltd. during the UPSI period, specifically between July 07, 2017, and July 10, 2017.

No, the applicants filed for settlement proposing to resolve the proceedings without admitting or denying the findings of fact and conclusions of law.

 
downloaded 245 times



Judgement posted by

Guest

Comments




CCI Pro



Company
21 October 2026
CA INTER/ BCOM WITH EXPERIENCE

CA S KUMAR GUPTA & CO

Amritsar

CA Inter

View Details
Company
Featured 07 November 2026
Paid Assisstant

DPV & Associates

Chennai

CA Inter

View Details
Company
Featured ARTICLESHIP 28 October 2026
CA- Inter and Articles

N N V Satish & Co.,

Hyderabad

CA Inter

View Details
Company
02 November 2026
Audit Executive

SRJP & Co LLP

Kochi

CA Inter

View Details
Company
ARTICLESHIP 28 October 2026
Article assistants

Shyam S Gupta and Company

New Delhi

CA Inter

View Details
Company
16 November 2026
Indirect Tax Associate

Sekhri Kanodia & Associates

Mumbai

B.Com

View Details
Company
ARTICLESHIP 07 November 2026
Article Assisstant

DPV & Associates

Chennai

CA Inter

View Details
Company
24 October 2026
CA Industrial Trainee

Fytomax Nutrition Private Limited

Aurangabad

CA Inter

View Details